Circulation, Vol 58, 770-776, Copyright © 1978 by American Heart Association
H Gavras, DP Faxon, J Berkoben, HR Brunner and TJ Ryan
The etiology of afterload elevation in congestive cardiac failure is
unclear, but experimental evidence suggests a role for the renin-
angiotensin system in maintaining elevated peripheral vascular resistance.
The angiotensin converting enzyme inhibitor SQ20,881 was administered to
eight patients with congestive cardiac failure (four hypertensives, four
normotensives) during or one day after diagnostic cardiac catheterization.
Various hemodynamic measurements performed before and during blockade
indicate that this agent caused improvement in cardiac function in all
patients by decreasing afterload. This improvement correlated with the
decrease in total vascular resistance but was independent of the baseline
blood pressure and plasma renin activity. These results suggest that
inhibition of angiotensin converting enzyme is a worthwhile approach to the
treatment of congestive heart failure, although its exact mechanism of
action remains unclear.
ARTICLES
Angiotensin converting enzyme inhibition in patients with congestive heart failure
This article has been cited by other articles:
 |
|
 |
|
  Z. Chen, P. A. Deddish, R. D. Minshall, R. P. Becker, E. G. Erdos, and F. Tan Human ACE and bradykinin B2 receptors form a complex at the plasma membrane FASEB J, November 1, 2006; 20(13): 2261 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfeffer and E. D. Frohlich Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2021 - H2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Erdos The ACE and I: how ACE inhibitors came to be FASEB J, June 1, 2006; 20(8): 1034 - 1038. [Full Text] [PDF]
|
|
|
|
|
|
I. Ignjacev-Lazich, E. Kintsurashvili, C. Johns, O. Vitseva, A. Duka, S. Shenouda, I. Gavras, and H. Gavras Angiotensin-converting enzyme regulates bradykinin receptor gene expression Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1814 - H1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Schwartz, A. Duka, I. Duka, J. Cui, and H. Gavras Novel targets of ANG II regulation in mouse heart identified by serial analysis of gene expression Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1957 - H1966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Jackman, M. G. Massad, M. Sekosan, F. Tan, V. Brovkovych, B. M. Marcic, and E. G. Erdos Angiotensin 1-9 and 1-7 Release in Human Heart: Role of Cathepsin A Hypertension, May 1, 2002; 39(5): 976 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gavras and H. R. Brunner Role of Angiotensin and Its Inhibition in Hypertension, Ischemic Heart Disease, and Heart Failure Hypertension, February 1, 2001; 37(2): 342 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Sabbah, W. C. Stanley, V. G. Sharov, T. Mishima, M. Tanimura, C. R. Benedict, S. Hegde, and S. Goldstein Effects of Dopamine {beta}-Hydroxylase Inhibition With Nepicastat on the Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Chronic Heart Failure Circulation, October 17, 2000; 102(16): 1990 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Weinsaft, M. F. O'Rourke, W. W. Nichols, A. M. Sharma, T. Pischon, S. Engeli, H. Gavras, S. Yusuf, and G. S. Francis Effect of Ramipril on Cardiovascular Events in High-Risk Patients N. Engl. J. Med., July 6, 2000; 343(1): 64 - 66. [Full Text]
|
|
|
|
 |
|
 C. A. Walker, F. A. Crawford Jr, and F. G. Spinale MYOCYTE CONTRACTILE DYSFUNCTION WITH HYPERTROPHY AND FAILURE: RELEVANCE TO CARDIAC SURGERY J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 388 - 400. [Full Text] [PDF]
|
|
|
|
|
|
N. J. Brown and D. E. Vaughan Angiotensin-Converting Enzyme Inhibitors Circulation, April 14, 1998; 97(14): 1411 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Manolis, C. Olympios, M. Sifaki, S. Handanis, D. Cokkinos, M. Bresnahan, I. Gavras, and H. Gavras Combined Sympathetic Suppression and Angiotensin-Converting Enzyme Inhibition in Congestive Heart Failure Hypertension, January 1, 1997; 29(1): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Manolis, C. Olympios, M. Sifaki, S. Handanis, M. Bresnahan, I. Gavras, and H. Gavras Suppressing Sympathetic Activation in Congestive Heart Failure : A New Therapeutic Strategy Hypertension, November 1, 1995; 26(5): 719 - 724. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. D. Minshall, F. Nakamura, R. P. Becker, and S. F. Rabito Characterization of Bradykinin B2 Receptors in Adult Myocardium and Neonatal Rat Cardiomyocytes Circ. Res., May 1, 1995; 76(5): 773 - 780. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. Simon, H. R. Black, M. Moser, and W. E. Berland Cough and ACE Inhibitors Arch Intern Med, August 1, 1992; 152(8): 1698 - 1700. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Munger, S. F. Gardner, and R. C. Jarvis Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure Journal of Pharmacy Practice, January 1, 1990; 3(5): 318 - 331. [Abstract] [PDF]
|
|
|
|
 |
|
 R. E. Shaddy, D. F. Teitel, and C. Brett Short-term Hemodynamic Effects of Captopril in Infants With Congestive Heart Failure Arch Pediatr Adolesc Med, January 1, 1988; 142(1): 100 - 105. [Abstract] [PDF]
|
|
|
|
 |
|
 G. S. FRANCIS, S. R. GOLDSMITH, T. B. LEVINE, M. T. OLIVARI, and J. N. COHN The Neurohumoral Axis in Congestive Heart Failure Ann Intern Med, September 1, 1984; 101(3): 370 - 377. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Marcic, P. A. Deddish, R. A. Skidgel, E. G. Erdos, R. D. Minshall, and F. Tan Replacement of the Transmembrane Anchor in Angiotensin I-converting Enzyme (ACE) with a Glycosylphosphatidylinositol Tail Affects Activation of the B2 Bradykinin Receptor by ACE Inhibitors J. Biol. Chem., May 19, 2000; 275(21): 16110 - 16118. [Abstract] [Full Text] [PDF]
|
|